Viking Therapeutics, Inc. (VKTX)
VKTX Stock Price Chart
Explore Viking Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VKTX price movements and trends.
VKTX Company Profile
Discover essential business fundamentals and corporate details for Viking Therapeutics, Inc. (VKTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2015
Employees
45.00
CEO
Brian Lian
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Financial Timeline
Browse a chronological timeline of Viking Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 21 Apr 2026
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 22 Oct 2025
EPS estimate is -$0.68.
Earnings released on 23 Jul 2025
EPS came in at -$0.58 falling short of the estimated -$0.44 by -31.82%.
Earnings released on 23 Apr 2025
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%.
Earnings released on 5 Feb 2025
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 23 Oct 2024
EPS came in at -$0.22 surpassing the estimated -$0.24 by +8.33%.
Earnings released on 24 Jul 2024
EPS came in at -$0.20 surpassing the estimated -$0.26 by +23.08%.
Earnings released on 24 Apr 2024
EPS came in at -$0.26 surpassing the estimated -$0.27 by +3.70%.
Earnings released on 7 Feb 2024
EPS came in at -$0.25 matching the estimated -$0.25, while revenue for the quarter reached $436.00K .
Earnings released on 25 Oct 2023
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 26 Jul 2023
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 26 Apr 2023
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 8 Feb 2023
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%.
Earnings released on 26 Oct 2022
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 27 Jul 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%.
Earnings released on 27 Apr 2022
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 9 Feb 2022
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%.
Earnings released on 3 Nov 2021
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%.
Earnings released on 28 Jul 2021
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%.
Earnings released on 28 Apr 2021
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%.
Earnings released on 17 Feb 2021
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $0.00 .
Earnings released on 28 Oct 2020
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%.
VKTX Stock Performance
Access detailed VKTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.